• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    6/11/24 8:06:21 AM ET
    $AKAN
    $FBLG
    $IGC
    $ISPC
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. The company's market cap stands at $26.7 million.
    • Purple Biotech (NASDAQ:PPBT) stock increased by 14.48% to $0.63. The market value of their outstanding shares is at $16.4 million.
    • Akanda (NASDAQ:AKAN) stock rose 12.54% to $3.05. The market value of their outstanding shares is at $5.8 million.
    • Viridian Therapeutics (NASDAQ:VRDN) shares rose 12.09% to $13.7. The market value of their outstanding shares is at $874.2 million.
    • IGC Pharma (AMEX:IGC) shares increased by 11.21% to $0.48. The company's market cap stands at $36.1 million.
    • OpGen (NASDAQ:OPGN) shares moved upwards by 10.67% to $2.8. The company's market cap stands at $3.7 million.

    Losers

    • ProKidney (NASDAQ:PROK) shares decreased by 12.9% to $2.63 during Tuesday's pre-market session. The market value of their outstanding shares is at $168.1 million.
    • Nuwellis (NASDAQ:NUWE) shares fell 10.42% to $0.18. The market value of their outstanding shares is at $3.3 million.
    • Virax Biolabs Group (NASDAQ:VRAX) stock fell 9.33% to $1.75. The company's market cap stands at $4.1 million.
    • SILO Pharma (NASDAQ:SILO) shares fell 8.47% to $1.08. The company's market cap stands at $3.9 million.
    • iSpecimen (NASDAQ:ISPC) shares decreased by 7.87% to $0.34. The company's market cap stands at $3.4 million.
    • FibroBiologics (NASDAQ:FBLG) stock declined by 7.58% to $8.05. The company's market cap stands at $263.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $FBLG
    $IGC
    $ISPC

    CompanyDatePrice TargetRatingAnalyst
    ProKidney Corp.
    $PROK
    12/16/2025$12.00Buy
    H.C. Wainwright
    Viridian Therapeutics Inc.
    $VRDN
    12/10/2025$42.00 → $47.00Outperform
    Wedbush
    Viridian Therapeutics Inc.
    $VRDN
    12/3/2025Outperform
    William Blair
    Viridian Therapeutics Inc.
    $VRDN
    11/24/2025Buy
    Truist
    Viridian Therapeutics Inc.
    $VRDN
    8/25/2025$44.00Buy
    Jefferies
    ProKidney Corp.
    $PROK
    6/30/2025$1.00Neutral → Underperform
    BofA Securities
    Virax Biolabs Group Limited
    $VRAX
    3/31/2025$3.00Buy
    H.C. Wainwright
    Viridian Therapeutics Inc.
    $VRDN
    12/19/2024$37.00 → $27.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $AKAN
    $FBLG
    $IGC
    $ISPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/5/26 8:00:15 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Tousignant Jennifer converted options into 5,169 shares and covered exercise/tax liability with 1,724 shares (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    3/4/26 7:17:16 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Chief Financial Officer Harmon Seth covered exercise/tax liability with 2,091 shares and converted options into 6,267 shares, increasing direct ownership by 116% to 7,790 units (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    3/4/26 7:15:18 PM ET
    $VRDN
    Medical Specialities
    Health Care

    $AKAN
    $FBLG
    $IGC
    $ISPC
    SEC Filings

    View All

    FibroBiologics Inc. filed SEC Form 8-K: Leadership Update

    8-K - FibroBiologics, Inc. (0001958777) (Filer)

    3/6/26 4:03:48 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by iSpecimen Inc.

    DEFA14A - iSpecimen Inc. (0001558569) (Filer)

    3/3/26 4:05:22 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CapForce Inc. (0001293818) (Filer)

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $AKAN
    $FBLG
    $IGC
    $ISPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

    HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that onboarding of the clinical sites has been completed for its Phase 1/2 clinical trial evaluating the safety and efficacy of CYWC628 for the treatment of refractory diabetic foot ulcers (DFUs). The clinical trial is a prospective, multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics' investigational topica

    3/5/26 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

    The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

    3/3/26 5:31:00 PM ET
    $AMGN
    $IRON
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AKAN
    $FBLG
    $IGC
    $ISPC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/5/26 8:00:15 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/4/26 5:50:10 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/3/26 8:00:20 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $FBLG
    $IGC
    $ISPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on ProKidney Corp. with a new price target

    H.C. Wainwright initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $12.00

    12/16/25 9:01:44 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wedbush reiterated coverage on Viridian Therapeutics with a new price target

    Wedbush reiterated coverage of Viridian Therapeutics with a rating of Outperform and set a new price target of $47.00 from $42.00 previously

    12/10/25 9:29:14 AM ET
    $VRDN
    Medical Specialities
    Health Care

    William Blair initiated coverage on Viridian Therapeutics

    William Blair initiated coverage of Viridian Therapeutics with a rating of Outperform

    12/3/25 8:40:59 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $AKAN
    $FBLG
    $IGC
    $ISPC
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKAN
    $FBLG
    $IGC
    $ISPC
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025

    MINNEAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced that it will release financial results for the third quarter 2025 on November 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-274-8461 (U.S) or 1-203-51

    10/23/25 9:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

    Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

    10/6/25 8:10:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AKAN
    $FBLG
    $IGC
    $ISPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 5:53:44 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 5:52:18 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Purple Biotech Ltd.

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    11/14/24 5:21:29 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care